Safety and efficacy of vaccinations in patients from high-risk groups: new challenges in the era of vaccine hesitancy
DOI:
https://doi.org/10.15584/ejcem.2019.1.14Keywords:
allergy, immunogenicity, preterm, safety, transplantation, vaccination, vaccine hesitancyAbstract
Introduction. Vaccinations are one of the most effective medical interventions that protect people against infectious diseases. It should be noted that a new vaccine licensing is always preceded by clinical trials assessing its safety and efficacy. Anti-vaccine propaganda carried out by vaccination opponents has become an international problem with a global reach.
Aim. To review the literature on vaccinations of patients from high-risk groups.
Material and methods. A literature review of the following databases has been conducted: EBSCO, PubMed, Science Direct, and Springer Link.
Results. High-risk groups in the paediatric population include pre-term born infants, patients after stem cell transplantations, children with allergies and other chronic diseases. Vaccinations in the examined groups are generally safe and are an effective method of preventing infections.
Conclusion. At a time when the level of vaccine skepticism is high and the epidemiological situation of many diseases is unstable, patients who are more susceptible to infection are particularly endangered. High level of knowledge of health care professionals and their personal positive attitude towards vaccinations are important for improving the vaccination coverage rates. In the light of measles epidemic outbreaks and an almost geometric increase in the number of pertussis cases noted recently, actions are needed to achieve herd immunity.
Downloads
References
Mantas A. Vaccine Hesitancy in Europe - European Health Management Association (EHMA). https://ehma.org/wp-content/uploads/2017/03/Vaccine-Hesitancy-in-Europe_-Final.pdf. Accessed February 1, 2019.
Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine. 2018;36(26):3861-3867.
Dubé E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy-Country-specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-6654.
Dubé E, Gagnon D, MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: Review of published reviews. Vaccine. 2015;33(34):4191-4203.
Coughlin MM, Beck AS, Bankamp B, Rota PA. Perspective on global measles epidemiology and control and the role of novel vaccination strategies. Viruses. 2017;9(1). doi:10.3390/v9010011.
ECDC. European Centre for Disease Prevention and Control. Monthly Measles and Rubella Monitoring Report, March 2019.; 2019.
PZH. Szczepienia. Info - PZH. www.szczepienia.pzh.gov.pl. Accessed February 1, 2019.
ECDC. European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU/EEA Member States – Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons. 2018. https://ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states. Accessed February 1, 2019.
Pfister RE, Aeschbach V, Niksic-Stuber V, Martin BC, Siegrist C-A. Safety of DTaP-based combined immunization in very-low-birth-weight premature infants: frequent but mostly benign cardiorespiratory events. J Pediatr. 2004;145(1):58-66.
PZH. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny w Warszawie – EPIMELD- Meldunki o Zachorowaniach Na Choroby Zakaźne, Zakażeniach i Zatruciach w Polsce z Lat 2014-2018. http://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html. Accessed February 1, 2019.
Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Hum Vaccines Immunother. 2015;11(11):2556-2563.
Tozzi AE, Piga S, Corchia C, et al. Timeliness of routine immunization in a population-based Italian cohort of very preterm infants: Results of the ACTION follow-up project. Vaccine. 2014;32(7):793-799.
Averbeck MA, Madersbacher H. Constipation and LUTS - how do they affect each other? Int Braz J Urol. 2011;37(1):16-28.
D’Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics. 1995;96(1 Pt 1):18-22. doi:7596716
Czajka H, Tarczoń I, Lauterbach R. Immunization in preterm infants--current knowledge. Med Wieku Rozwoj. 2008;12(2 Pt 2):643-652.
Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 2003;112(1 Pt 1):193-198.
Szczapa J, Jackowska T, Szenborn L, et al. HE. Szczepienie dzieci przedwcześnie urodzonych oraz z małą urodzeniową masą ciała. Pediatr Pol. 2011;86(5):506-516.
Borszewska-Kornacka MK, Wilińska M, Kalisiak M, Baszczeska J, Witwicki J, Klemińska-Nowak M. Jak neonatolodzy realizują szczepienia noworodków przedwcześnie urodzonych. Pediatr Pol - Polish J Paediatr. 2018;93(1):51-56.
Czajka H, Lauterbach R, Pawlik D, Radziszewska R. Implementation of mandatory vaccinations against diphtheria, tetanus and pertussis in preterm infants as part of the Polish Immunization Programme. Pediatr Pol. 2017;92(5):485-493.
Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health. 1997;33(5):418-421.
Martinón-Torres F, Wysocki J, Center KJ, et al. Circulating antibody 1 and 2 years after vaccination with the 13-valent pneumococcal conjugate vaccine in preterm compared with term infants. Pediatr Infect Dis J. 2017;36(3):326-332.
Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015;135(4):e876-86.
Czajka H, Czajka S, Dyląg KA, Borek E, Kuchar E. Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement. Adv Exp Med Biol. 2019. doi:10.1007/5584_2019_344
Ljungman P, Aschan J, Gustafsson B, Lewensohn-Fuchs I, Winiarski J, Ringdén O. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2004;34(12):1067-1069.
Machado CM, Cardoso MRA, da Rocha IF, Boas LS V, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36(10):897-900.
Gozdzik J, Czajka H, Paradowska-Stankiewicz I, et al. Status of immunity for vaccine--preventable diseases in children after hematopoietic stem cells transplantation. Przegl Epidemiol. 2012;66(1):93-98.
Goździk J, Czajka H, Skoczeń S, et al. Safety and efficacy of vaccination in children after stem cell transplantation. Part 1. Med Wieku Rozwoj. 2010;14(1):42-52.
Diaz-Mitoma F, Halperin SA, Scheifele D. Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can J Infect Dis. 2000;11(2):97-101.
Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009;27(47):6504-6511.
Miller E. MMR vaccine: review of benefits and risks. J Infect. 2002;44(1):1-6.
Crovari P, Gabutti G, Giammanco G, et al. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. Vaccine. 2000;18(25):2796-2803.
Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol. 2007;165(6):704-709.
Czajka H, Wysocki J. Zespół hipotoniczno-hiporeaktywny (HHE) po zastosowaniu skojarzonej, pełnokomórkowej szczepionki przeciwko błonicy, tężcowi i krztuścowi (DTPw). Neurol Neurochir Pol. 2004;38(1):17-24.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
